Pfizer (NYSE:PFE) Q4 2022 Revenue Rose 1.9% to $24.29 Billion, Below the FactSet Consensus $24.38 Bln。

January 31, 2023 — Pfizer Inc. (NYSE:PFE) reported exceptional financial results for fourth-quarter and full-year 2022 and provided 2023 financial guidance. Pfizer Inc. (NYSE:PFE) reported Q4 adjusted earnings  of $1.14 per diluted share, up from $0.79 a year earlier. Analysts polled by Capital IQ expected $1.04. Revenue for the quarter was $24.29 billion, up from $23.84 billion a year earlier. Analysts surveyed by Capital IQ expected $24.40 billion. The company said it is expecting fiscal 2023 adjusted earnings of $3.25 to $3.45 per diluted share. Analysts polled by Capital IQ are expecting $4.38. Revenue for the year is expected to range between $67 billion and $71 billion. Analysts surveyed by Capital IQ are expecting $74.23 billion. Fourth-Quarter 2022 Revenues of $24.3 Billion, Reflecting 13% Operational Growth，Excluding Contributions from Paxlovid and Comirnaty(1), Revenues Grew 5% Operationally。 Full-Year 2022 Revenues of $100.3 Billion, An All-Time High for Pfizer, Reflecting 30% Operational Growth，Excluding Contributions